Resolvin D1 reverses reactivity and CA2+ sensitivity induced by ET-1, TNF-α, and IL-6 in the human pulmonary artery

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 11, 2014, Pages H1547-H1558

  Hiram, Roddy ^a   Rizcallah, Edmond ^a   Sirois, Chantal ^a   Sirois, Marco ^a   Morin, Caroline ^a,b   Fortin, Samuel ^b   Rousseau, Eric ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b SCF Pharma   (Canada)

Author keywords

CPI 17; Docosapentanenoic acid monoacylglyceride; Endothelin; Endothelin 1; Interleukin 6; Pulmonary hypertension; Resolvin D1; Tumor necrosis fac tor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANTIINFLAMMATORY AGENT; CALCIUM ION; DOCOSAPENTAENOIC ACID; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 32; INTERLEUKIN 6; MEMBRANE PROTEIN; POTASSIUM CHLORIDE; RESOLVIN D1; SEROTONIN; TRANSMEMBRANE PROTEIN MEMBER 16A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANO1 PROTEIN, HUMAN; CHLORIDE CHANNEL; DOCOSAHEXAENOIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PPP1R14A PROTEIN, HUMAN; TUMOR PROTEIN; UNSATURATED FATTY ACID;

ARTERIAL PRESSURE; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EC50; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; VASOCONSTRICTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CALCIUM SIGNALING; CYTOLOGY; DRUG EFFECTS; GENETICS; SMOOTH MUSCLE FIBER;

CALCIUM SIGNALING; CHLORIDE CHANNELS; DOCOSAHEXAENOIC ACIDS; ENDOTHELIN-1; FATTY ACIDS, UNSATURATED; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-6; MYOCYTES, SMOOTH MUSCLE; NEOPLASM PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PULMONARY ARTERY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84913542948     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00452.2014     Document Type: Article

References (46)

1. Arnold C, Markovic M, Blossey K, Wallukat G, Fisher R, Dechend R, Konkel A, Von Schaky C, Luft CF, Muller DN, Rothe M, Schunk WH. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of &)-3 fatty acids. J Biol Chem285: 32720-32733, 2010.
2. Bulley S, Neeb ZP, Burris SK, Bannister JP, Thomas-Gatewood CM, Jangsangthong W, Jaggar JH. TMEM16A/ANO1 channels contribute to the myogenic response in cerebral arteries. Circ Res111: 1027-1036, 2012.
3. Braun UM, Szalai P, Strasser RH, Borst MM. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res59: 658-667, 2013.
4. Calder CP. n-3 polyunsatured fatty acids, inflammation and inflammatory diseases. Am J Clin Nutr83: 1505-1519, 2003.
5. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol35: 49-53, 2000.
6. Claria J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol189: 2597-2605, 2012.
7. Courboulin A, Paulin R, Giguere N, Saksouk N, Perreault T, Meloche J, Paquet E, Biardel S, Provencher S, Cote J, Simard M, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med208: 535-548, 2011.
8. Fredmann G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J437: 185-197, 2011.
9. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res61: 227-237, 2004.
10. Geleijnse JM, Giltay EJ, Grobbee DE. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hy-pertens20: 1493-1499, 2002.
11. Gray MA, Winpenny JP. The anoctamin (TMEM16) gene family: calcium-activated choride channels come of age. Exp Physiol97: 175-176, 2012.
12. Guibert C, Savineau JP, Crevel H, Marthan R, Rousseau E. Effect of short-term organoid culture on the pharmaco-mechanical properties of rat extra- and intrapulmonary arteries. Br J Pharmacol146: 692-701, 2005.
13. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin-23, interferon-g and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol8: 873-879, 2008.
14. Hoeper MM. The new definition of pulmonary hypertension. Eur Respir J34: 790-791, 2009.
15. Humbert M, Morell NW, Archer SL, Stenmark KR, Maclean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol43: 13S-24S, 2004.
16. Kitazawa T, Eto M, Woodsome TP, Brautigan LD. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem275: 9897-9900, 2000.
17. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol158: 960-971, 2009.
18. Lee CH. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res35: 3-7, 2012.
19. Lee HJ, Park MK, Lee EJ, Lee CH. Resolvin D1 inhibits TGF-fj1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int J Biochem Cell Biol45: 2801-2807, 2013.
20. Makhlouf GM. Ca2+ release and contraction induced by IP3 and contractile agonists in mammalian gastric smooth muscle. Mol Cell Biochem82: 137-143, 1988.
21. Morin C, Fortin S, Rousseau E. 19,20-EpDPE, a bioactive CYP450 metabolite of DHA monoacyglyceride, decreases Ca2+ sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol301: H1311-H1318, 2011.
22. Morin C, Fortin S, Rousseau E. Docosahexaenoic acid monoacylglyc-eride decreases endothelin-1-induced Ca2+ sensitivity and proliferation in human pulmonary arteries. Am J Hypertens7: 757-763, 2012.
23. Morin C, Guilbert C, Sirois M, Echave V, Gomes MM, Rousseau E. Effects of M-hydroxylase product on distal human pulmonary arteries. Am J Physiol Heart Circ Physiol294: H1435-H1443, 2008.
24. Morin C, Hiram R, Rousseau E, Blier P, Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol; doi:10.1152/ajpheart.00814.2013.
25. Morin C, Rousseau E, Fortin S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids89: 203-213, 2013.
26. Morin C, Sirois M, Echave V, Albadine R, Rousseau E. 17,18-epoxyeicosatetraenoic acid targets PPAR-y and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol43: 564-575, 2010.
27. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol38: 192-201, 2009.
28. Morin C, Sirois M, Echave V, Rizcallah E, Rousseau E. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol296: L130-L139, 2009.
29. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol58: 2047-2046, 2011.
30. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA79: 944-948, 1979.
31. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of PKC. Science258: 607–614, 1992.
32. Nowak JZ. Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Postepy Hig Med Dosw64: 115–132, 2010.
33. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest141: 210–221, 2012.
34. Pritchard HAT, Albert AP, Leblanc N, Greenwood Iain A. Inhibitory role of PIP2 on calcium-activated chloride channel activity. Biophys J106: 144a, 2014.
35. Qu X, Zhang X, Yao J, Song J, Nikolic-Paterson D, Li J. Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol228: 506–519, 2012.
36. Rodat-Despoix L, Aires V, Ducret T, Marthan R, Savineau JP, Rousseau E, Guibert C. Signalling pathways involved in the contractile response to 5-HT in human pulmonary artery. Eur Respir J34: 1338–1347, 2009.
37. Rogerio AP, Haworth O, Croze R, Oh SF, Uddin M, Carlo T, Pfeffer MA, Priluck R, Serhan CN, Levy BD. Resolvin D1 and its aspirin-triggered epimer AT-RvD1 promote the resolution of allergic airways responses. J Immunol189: 1983–1991, 2012.
38. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol8: 349–361, 2008.
39. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory–pro-resolving mediators and their receptors. Curr Top Med Chem11: 629–647, 2011.
40. Shi Y, Wang C, Han S, Pang B, Zhang N, Wang J, Li J. Determination of PKC isoform-specific protein expression in pulmonary arteries of rats with chronic hypoxia-induced pulmonary hypertension. Med Sci Monit18: BR69–BR75, 2012.
41. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res107: 1170–1184, 2010.
42. Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med11: S85–S90, 2010.
43. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr3: 1–7, 2012.
44. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature389: 990–994, 1997.
45. Wei B, D’Amico T, Samad Z, Hasan R, Berry MF. The impact of pulmonary hypertension on morbidity and mortality following major lung resection. Eur J Cardiothorac Surg10: 1093–95, 2013.
46. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med16: 592–597, 2010.